Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts

The Movember Foundations Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium

Research output: Contribution to journalArticle

Abstract

Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.

Original languageEnglish (US)
Pages (from-to)693-702
Number of pages10
JournalEuropean Urology
Volume76
Issue number5
DOIs
StatePublished - Nov 1 2019

Keywords

  • Active surveillance
  • Decision curve analyses
  • Disease reclassification
  • External validation
  • Low-risk prostate cancer
  • Net benefit
  • Prostate biopsy
  • Risk calculator

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts'. Together they form a unique fingerprint.

  • Cite this